A Study to Assess the Efficacy and Safety of HMI-115 in Male Subjects With Androgenetic Alopecia

A Randomized, Multicenter, Double-blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety, Tolerability and Efficacy in Male Androgenetic Alopecia Treated With HMI-115 Over a 24-Week Treatment Period

To investigate the efficacy of HMI-115 compared to placebo in treating Androgenic Alopecia patients for 24 weeks

Study Overview

• Status: Completed
• Conditions: Androgenetic Alopecia
• Intervention / Treatment: Drug: placebo-Q2W; Drug: HMI-115-120mg-Q4W; Drug: HMI-115-240mg-Q4W; Drug: HMI-115, 240mg-Q2W

• Study Type: Interventional
• Enrollment (Actual): 192
• Phase: Phase 2

Contacts and Locations

Study Locations

• China
  • Beijing
    • Beijing, Beijing, China, 100035
      • Peking University People's Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Must have given written informed consent before any study-related activities are carried out and must be able to understand the full nature and purpose of the trial, including possible risks and adverse effects.
2. Male subjects, between 18 and 65 years of age, inclusive, at the time of signing informed consent.
3. Clinical diagnosis of androgenetic alopecia. Male subjects who meet Norwood-Hamilton scales III vertex, IV and V .
4. Be willing and able to comply with all study assessments and adhere to the protocol schedule and restrictions, including having a small circle about 1 cm2 of hair clipped to approximate 1 mm in length and micro-dot-tattoo on the scalp of target area.
5. Subjects who are willing to keep the same hair color, refrain from hair weaving, and hair growth therapy and supplement (except for protocol specified IMP) during the study.
6. Subjects agree to use required birth control methods from signing the consent until 3 months after the last dose of IMP or complete whole study period whichever is longer.

Exclusion Criteria:

1. Subject with history of scalp radiation or surgery which could interfere study assessment (e.g., hair transplantation surgery).
2. Subject with history of scalp laser treatment within 6 months prior screening, including but not limited to, low level laser, and fractional laser, etc.
3. Subject with history of hair weaves within 3 months prior screening.
4. Subject has a current history of hyperthyroidism or uncontrolled hypothyroidism.
5. Subject has, in the Investigator's opinion, uncontrolled hypertension (systolic blood pressure [SBP] > 159 mmHg, diastolic blood pressure [DBP] > 99 mmHg).

6. Subject has any of the following conditions within 6 weeks prior to Screening:

   1. Myocardial infarction, stroke, unstable angina, or transient ischemic attack.
   2. Heart failure with classified as being in New York Heart Association Class III or IV.
7. Subject has high fever, major surgery, or ten percent or more weight decrease within three months before screening.
8. Subject with history of active malignancy (with or without systemic chemotherapy), except treated basal cell carcinoma of the skin (besides scalp).
9. Subject plans to schedule elective surgery during the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: placebo-Q2W; placebo, 0mg/vials	Drug: placebo-Q2W; placebo, 0mg，SC，Q2W，12 cycles
Active Comparator: HMI-115-120mg-Q4W; HMI-115, 60mg/vials	Drug: HMI-115-120mg-Q4W; HMI-115, 120mg，SC，Q4W，6 cycles(Placebo given in the second week of each cycle)
Active Comparator: HMI-115-240mg-Q4W; HMI-115, 60mg/vials	Drug: HMI-115-240mg-Q4W; HMI-115, 240mg，SC，Q4W，6 cycles(Placebo given in the second week of each cycle)
Active Comparator: HMI-115-240mg-Q2W; HMI-115, 60mg/vials	Drug: HMI-115, 240mg-Q2W; HMI-115, 240mg，SC，Q2W，12 cycles

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The Rate of Target Arean Hair Count (TAHC)	The mean change in TAHC of non-vellus from baseline	24 Weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Hair Growth State Assessed by Hair Growth Questionnaire Assessment (HGQA)	To assess the hair growth by 7-question questionnaire and summary the number and percentage of subjects in each category for each HGQA question.	6 weeks, 12 weeks, 18 weeks, 24 weeks, and 36 weeks
Target Area Hair Count (TAHC) change from baseline	The mean change in TAHC of non-vellus from Baseline	6 weeks, 12 weeks, 18 weeks, 24 weeks, and 36 weeks
Rate of Target Area Hair Width (TAHW)	The mean change in TAHW of non-vellus from baseline	6 weeks, 12 weeks, 18 weeks, 24 weeks, and 36 weeks
Investigator Global Assessment (IGA)	Summary of subject number and percentage in each IGA category	6 weeks, 12 weeks, 18 weeks, 24 weeks, and 36 weeks
Subject Self-Assessment (SSA)	Summary of subject number and percentage in each SSA category	6 weeks, 12 weeks, 18 weeks, 24 weeks, and 36 weeks
Norwood-Hamilton Grade change from baseline	Summary of subject number and percentage in each grade of Norwood-Hamilton Scale	12 weeks, 24 weeks, and 36 weeks
Frequencies and percentages of Adverse event (AE)	Frequency and percentages of subjects with treatment-emergent AE (TEAE) will be calculated and TEAE will be summarized by systematic organ classification (SOC), preferred term (PT), relationship to study treatment, maximum severity, whether resulting in death, whether resulting in study treatment discontinuation, belong to serious AE (SAE) or not, belong to events of special interest (AESI) or not.	36Weeks
Blood Pressure change from baseline	Descriptive statistics summarizing changes in blood pressure (systolic and diastolic) will be compared between baseline levels and each predetermined time point.	36 Weeks
Pulse change from baseline	Descriptive statistics summarizing changes in pulse will be compared between baseline levels and each predetermined time point.	36 Weeks
Body temperature change from baseline	Descriptive statistics summarizing changes in body temperature will be compared between baseline levels and each predetermined time point.	36 Weeks
Respiratory rate	Descriptive statistics summarizing changes in respiratory rate will be compared between baseline levels and each predetermined time point.	36 Weeks
Complete or brief physical examination, at a minimum of General appearance, HEENT (head, eyes, ears, nose, throat), Neck, Lung/pulmonary, Chest, Neurological or not, Extremities,ect.to assess the physical health state.	Physical examination findings by body system will be summarized, presented with frequency counts and percentages. A complete or brief physical examination will be performed at Visit 1, Visit 2, End of Treatment Visit and Follow-up Visit. Height (cm) and weight (kg) will be measured and body mass index will be calculated and recorded at specified period.	36 Weeks
Concomitant Medication	Concomitant medication usage will be summarized by the number and proportion of subjects and classified by the World Health Organization Drug Dictionary (WHO DD) based on Anatomical Therapeutic Chemical Classification System (ATC) code level 3.	36 Weeks
Change in twelve-lead electrocardiogram parameters	Change in electrocardiogram parameters including heart rate (HR), QRS, RR, PR, and QT interval (QTcF and QTcB) relative to baseline will be summarized descriptively by visits and groups. The within-group changes from baseline to each visit will be summarized and will be compared with a paired t-test for continuous measurements. Subject number and percentage with other clinically significant electrocardiogram findings in each visit will be summarized by groups. A general assessment of the 12-lead electrocardiogram will be presented as normal, abnormal clinical significance, or abnormal no clinical significance.	36 Weeks
Clinical laboratory tests of hematology	Descriptive statistics summarizing changes in results of clinical laboratory tests of hematology from baseline levels at each predetermined time point. Shift tables for changes from baseline according to the normal minimum and maximum will be provided.	36 Weeks
Clinical laboratory tests of coagulation	Descriptive statistics summarizing changes in results of clinical laboratory tests of coagulation from baseline levels at each predetermined time point. Shift tables for changes from baseline according to the normal minimum and maximum will be provided.	36 Weeks
Clinical laboratory tests of clinical chemistry	Descriptive statistics summarizing changes in results of clinical laboratory tests of clinical chemistry from baseline levels at each predetermined time point. Shift tables for changes from baseline according to the normal minimum and maximum will be provided.	36 Weeks
Clinical laboratory tests of urinalysis	Descriptive statistics summarizing changes in results of clinical laboratory tests of urinalysis from baseline levels at each predetermined time point. Shift tables for changes from baseline according to the normal minimum and maximum will be provided.	36 Weeks
Clinical laboratory tests of hormones	Descriptive statistics summarizing changes in results of clinical laboratory tests of hormones from baseline levels at each predetermined time point. Shift tables for changes from baseline according to the normal minimum and maximum will be provided.	36 Weeks

Collaborators and Investigators

• Sponsor: Hope Medicine (Nanjing) Co., Ltd

Study record dates

Study Major Dates

• Study Start (Actual): September 11, 2023
• Primary Completion (Actual): August 26, 2024
• Study Completion (Actual): November 28, 2024

Study Registration Dates

• First Submitted: October 16, 2023
• First Submitted That Met QC Criteria: November 3, 2023
• First Posted (Actual): November 7, 2023

Study Record Updates

• Last Update Posted (Actual): June 4, 2025
• Last Update Submitted That Met QC Criteria: June 3, 2025
• Last Verified: June 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathological Conditions, Anatomical; Skin Diseases; Hypotrichosis; Hair Diseases; Alopecia Areata; Alopecia
• Other Study ID Numbers: HMI-115AG201

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No